Vytorin vs. Praluent
See how Vytorin and Praluent compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Vytorin is a daily pill combining a statin and a cholesterol absorption inhibitor, while Praluent is a self-injected PCSK9 inhibitor given every two to four weeks.
Praluent carries an FDA-approved indication for reducing heart attack, stroke, and hospitalization risk in people with existing cardiovascular disease, a claim Vytorin's label does not include.
Vytorin's main risks relate to statin-linked muscle and liver effects, while Praluent's most common side effects are cold-like symptoms and injection site reactions.
Vytorin vs. Praluent Drug Summary
Vytorin
Vytorin combines the statin simvastatin with the cholesterol absorption inhibitor ezetimibe in one daily tablet. It is FDA-approved to lower LDL cholesterol, total cholesterol, and triglycerides in primary hyperlipidemia, as well as to treat homozygous familial hypercholesterolemia and sitosterolemia.
Praluent
Praluent is a PCSK9 inhibitor given as a self-injection every two weeks or, at a higher dose, once a month. It is FDA-approved to lower LDL cholesterol as an add-on to statin therapy, treat heterozygous familial hypercholesterolemia, and reduce cardiovascular event risk in adults with established heart disease.
Vytorin vs. Praluent Side Effects
Vytorin
Praluent
Vytorin vs. Praluent Dosage
Vytorin
Praluent
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg/10 mg | At the start |
| Maximum dose | 10 mg/80 mg | If needed |
| Dose changes | 3 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 75 mg | At the start |
| Maximum dose | 300 mg | If needed |
| Dose changes | 2 increases | As tolerated |
Vytorin
| STAGE | DOSE | WHEN |
| Starting dose | 10 mg/10 mg | At the start |
| Maximum dose | 10 mg/80 mg | If needed |
| Dose changes | 3 increases | As tolerated |
Praluent
| STAGE | DOSE | WHEN |
| Starting dose | 75 mg | At the start |
| Maximum dose | 300 mg | If needed |
| Dose changes | 2 increases | As tolerated |
Vytorin vs. Praluent Indications
Vytorin
Vytorin is approved for people with primary hyperlipidemia who need to lower LDL, total cholesterol, and triglycerides while raising HDL. It also treats two rare inherited conditions, homozygous familial hypercholesterolemia and homozygous sitosterolemia. It is not approved for use in active liver disease.
Lowers LDL, total cholesterol, and triglycerides
Raises HDL cholesterol
Treats homozygous familial hypercholesterolemia
Treats homozygous sitosterolemia
Praluent
Praluent is approved as an add-on to maximally tolerated statin therapy for adults with primary hyperlipidemia who need further LDL lowering. It also treats heterozygous familial hypercholesterolemia in patients 8 and older and reduces the risk of heart attack, stroke, and hospitalization for unstable angina in adults with established cardiovascular disease.
Add-on LDL lowering with statin therapy
Treats heterozygous familial hypercholesterolemia (ages 8+)
Reduces risk of heart attack and stroke
Reduces hospitalization for unstable angina
Vytorin vs. Praluent Pros and Cons
Vytorin
Vytorin pairs a statin with a cholesterol absorption inhibitor in one daily pill, giving two mechanisms of LDL reduction without an injection. It carries the class risks of statins, including muscle aches and liver enzyme changes, and its highest dose is reserved for patients who already tolerate it well. As an oral combination pill, it is typically a more familiar first-line option for insurance coverage than an injectable biologic.
Pros
Oral tablet with no injections needed
Combines two LDL-lowering mechanisms in one pill
Multiple dose strengths to match different LDL goals
Approved for homozygous familial hypercholesterolemia and sitosterolemia
Cons
Carries statin risk of myopathy and rhabdomyolysis
Requires liver enzyme monitoring due to hepatotoxicity risk
Interacts with strong CYP3A4 inhibitors, limiting other medications
Not FDA-approved specifically for cardiovascular event reduction
Praluent
Praluent is a self-injected antibody that blocks PCSK9, lowering LDL cholesterol and carrying proven cardiovascular outcome data. It avoids statin-related liver and muscle risks but requires learning self-injection and cold storage of the pen. As a biologic with no generic version, it usually needs prior authorization from insurance before it is covered.
Pros
FDA-approved to reduce risk of heart attack, stroke, and unstable angina hospitalization
Avoids statin-related liver and muscle monitoring requirements
Flexible dosing: every 2 weeks or once monthly
Approved for heterozygous familial hypercholesterolemia starting at age 8
Cons
Requires self-injection rather than a pill
Pen must be refrigerated until ready to use
Not approved for homozygous familial hypercholesterolemia
No generic or biosimilar version currently available
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.